Patient experiences and clinician views on the role of radiation therapy for ductal carcinoma in situ Journal Article


Authors: Shumway, D. A.; McLeod, C. M.; Morrow, M.; Li, Y.; Kurian, A. W.; Sabolch, A.; Hamilton, A. S.; Ward, K. C.; Katz, S. J.; Hawley, S. T.; Jagsi, R.
Article Title: Patient experiences and clinician views on the role of radiation therapy for ductal carcinoma in situ
Abstract: Purpose: To evaluate patient experiences with decisions regarding radiation therapy (RT) for ductal carcinoma in situ (DCIS), and to assess clinician views on the role of RT for DCIS with favorable features in the present era. Methods and Materials: A sample of women with newly diagnosed breast cancer from the population-based Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries were sent surveys approximately 2 months after undergoing breast-conserving surgery (BCS), with a 70% response rate. The analytic sample was limited to 538 respondents with unilateral DCIS. We also surveyed 761 surgeons and radiation oncologists treating breast cancer in those regions, of whom, 539 responded (71%). Results: After BCS, 23% of patients omitted RT, with twice the rate of omission in Los Angeles County relative to Georgia (31% vs 16%; P <.001). The most common reasons for omitting RT were advice from a clinician that it was not needed (62%) and concern about side effects (24%). Cost and transportation were not reported as influential considerations. After covariate adjustment, low- and intermediate-grade disease (odds ratio [OR] 5.5, 95% confidence interval [CI] 2.5-12; and OR 3.2, 95% CI 1.7-6.1, respectively) and Los Angeles County SEER site (OR 4.3, 95% CI 2.3-8.2) were significantly associated with greater RT omission. Of the responding clinicians, 62% would discuss RT omission for a patient with DCIS with favorable features. Clinicians in Los Angeles County were more likely to discuss RT omission than were those in Georgia (67% vs 56%; P =.01). Approximately one third of clinicians would obtain the Oncotype DX DCIS score. Conclusions: The heterogeneity in RT omission after BCS for DCIS continues to be substantial, with systematic differences in provider opinions across the 2 regions we studied. Enhanced precision of recurrence estimates, guidance from professional organizations, and better communication are needed to improve the consistency of treatment in this controversial area. © 2018 Elsevier Inc.
Keywords: adult; aged; cancer surgery; major clinical study; cancer recurrence; multimodality cancer therapy; cancer patient; cancer radiotherapy; cancer staging; radiotherapy; health survey; confidence interval; partial mastectomy; medical society; cancer registry; cancer epidemiology; estrogen receptor; patient treatment; personal experience; intraductal carcinoma; diseases; radiation oncologists; ductal carcinoma in situ; lumpectomy; breast conserving surgery; surveys; response rate; cancer prognosis; patient experiences; methods and materials; human; female; priority journal; article; radiation oncologist; professional organization
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 100
Issue: 5
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2018-04-01
Start Page: 1237
End Page: 1245
Language: English
DOI: 10.1016/j.ijrobp.2018.01.020
PROVIDER: scopus
PUBMED: 29439886
PMCID: PMC8603836
DOI/URL:
Notes: Article -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Monica Morrow
    772 Morrow